Indoor life is comfortable for pet birds, but it comes with one big downside: most homes don’t provide the kind of light ...

A San Diego startup may have created what the scientific community has talked about for decades – a kind of universal flu ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Shares of global pharmaceutical company Merck (NYSE:MRK) jumped 4.1% in the afternoon session after Wells Fargo upgraded the stock to "Overweight" from "Equal-Weight," citing confidence in the company ...

Merck's newest acquisition grants it access to a highly promising medicine. That could help it overcome the challenges its two biggest franchises are facing. Merck has other things going its way, ...

Merck on Monday announced the groundbreaking of its new Virginia pharmaceutical manufacturing facility, a cornerstone of the company’s $70 billion U.S. investment strategy. The 400,000-square-foot ...

Merck & Co. will build a $3 billion pharmaceutical manufacturing facility in Elkton that is expected to create 500 jobs, Gov. Glenn Youngkin and the company announced at a ceremonial groundbreaking ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. BERLIN — At a prime-time session on Saturday at a major cancer conference ...

Merck is attractively valued, boasting strong free cash flow, robust margins, and a leading position in oncology with Keytruda. MRK faces a looming patent cliff for Keytruda in 2028, but a strong late ...

Merck (NYSE:MRK) said that the FDA has cleared Keytruda Qlex, a new subcutaneous version of its blockbuster cancer drug, offering a faster alternative to IV infusion, a company spokesperson confirmed ...